

Case Number:	CM14-0174295		
Date Assigned:	10/28/2014	Date of Injury:	02/11/2012
Decision Date:	12/05/2014	UR Denial Date:	10/01/2014
Priority:	Standard	Application Received:	10/22/2014

HOW THE IMR FINAL DETERMINATION WAS MADE

MAXIMUS Federal Services sent the complete case file to an expert reviewer. He/she has no affiliation with the employer, employee, providers or the claims administrator. The expert reviewer is Board Certified in Occupational Medicine and is licensed to practice in California. He/she has been in active clinical practice for more than five years and is currently working at least 24 hours a week in active practice. The expert reviewer was selected based on his/her clinical experience, education, background, and expertise in the same or similar specialties that evaluate and/or treat the medical condition and disputed items/services. He/she is familiar with governing laws and regulations, including the strength of evidence hierarchy that applies to Independent Medical Review determinations.

CLINICAL CASE SUMMARY

The expert reviewer developed the following clinical case summary based on a review of the case file, including all medical records:

According to the records made available for review, this is a 66-year-old male with a 2/11/12 date of injury. At the time (10/1/14) of request for authorization for Cyclobenzaprine/Lidocaine 10%/3%/5% 120gm, there is documentation of subjective (low back pain rated 5/10) and objective (lumbar spine tenderness to palpation over the midline, positive straight leg raise at 40 degrees, and diminished sensation over the left-sided L4, L5, and S1 dermatomes; positive tenderness to light touch) findings, current diagnoses (lumbar spine disc protrusion and lumbar spine radiculopathy, phantom limb pain, rule out RSD; status post left toe amputation), and treatment to date (activity modification, aquatic therapy, and medications (including ongoing use of Omeprazole and Gabapentin)).

IMR ISSUES, DECISIONS AND RATIONALES

The Final Determination was based on decisions for the disputed items/services set forth below:

Cyclobenzaprine/Lidocaine 10%/3%/5% 120gm: Upheld

Claims Administrator guideline: Decision based on MTUS Chronic Pain Treatment Guidelines Topical Analgesics Page(s): 111-113.

MAXIMUS guideline: Decision based on MTUS Chronic Pain Treatment Guidelines Topical Analgesics Page(s): 111-113.

Decision rationale: MTUS Chronic Pain Medical Treatment Guidelines identifies that many agents are compounded as monotherapy or in combination for pain control; that Ketoprofen, Lidocaine (in creams, lotion or gels), Capsaicin in a 0.0375% formulation, Baclofen and other muscle relaxants, and Gabapentin and other antiepilepsy drugs are not recommended for topical applications; and that any compounded product that contains at least one drug (or drug class) that is not recommended, is not recommended. Within the medical information available for review, there is documentation of diagnoses of lumbar spine disc protrusion and lumbar spine radiculopathy, phantom limb pain, rule out RSD; status post left toe amputation. However, Cyclobenzaprine/Lidocaine 10%/3%/5% 120gm contains at least one drug (Lidocaine) and one drug class (muscle relaxants (Cyclobenzaprine)) that is not recommended. Therefore, based on guidelines and a review of the evidence, the request for Cyclobenzaprine/Lidocaine 10%/3%/5% 120gm is not medically necessary.